Acute respiratory distress syndrome
Acute respiratory distress syndrome
复制标题
DOI：
10.1007/s00108-012-3018-5
复制
发表时间：
2012-05-01
期刊：
影响因子：
--
通讯作者：
Mayer, K.
中科院分区：
文献类型：
--
作者：
Hecker, M.;Weigand, M. A.;Mayer, K.
急性呼吸窘迫综合征（ARDS）是由多种对肺的直接和间接损伤所导致的急性肺损伤的临床表现。ARDS的主要临床特征是顽固性动脉低氧血症，这是由于血管渗漏和功能障碍，导致通气与血流灌注匹配受损，进而引起富含蛋白质的肺泡水肿以及表面活性物质功能受损的结果。对ARDS病理生理学的更好理解促使了新疗法、药物策略的研发以及机械通气的进步。然而，保护性通气是ARDS治疗中唯一被证实可提高生存率的选择，且很少有其他疗法能转化为改善氧合或减少通气时间。创新治疗选择的发展，如体外膜肺氧合，有可能进一步提高这种毁灭性疾病的生存率。
Acute respiratory distress syndrome (ARDS) is the clinical manifestation of an acute lung injury caused by a variety of direct and indirect injuries to the lung. The cardinal clinical feature of ARDS, refractory arterial hypoxemia, is the result of protein-rich alveolar edema with impaired surfactant function, due to vascular leakage and dysfunction with consequently impaired matching of ventilation to perfusion. Better understanding of the pathophysiology of ARDS has led to the development of novel therapies, pharmacological strategies, and advances in mechanical ventilation. However, protective ventilation is the only confirmed option in ARDS management improving survival, and few other therapies have translated into improved oxygenation or reduced ventilation time. The development of innovative therapy options, such as extracorporeal membrane oxygenation, have the potential to further improve survival of this devastating disease.